Medical - Devices
Compare Stocks
4 / 10Stock Comparison
ADGM vs DBVT vs ALKS vs BEAT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Healthcare Information Services
ADGM vs DBVT vs ALKS vs BEAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Biotechnology | Biotechnology | Medical - Healthcare Information Services |
| Market Cap | $15M | $1712.35T | $5.90B | $35M |
| Revenue (TTM) | $-143K | $0.00 | $1.56B | $0.00 |
| Net Income (TTM) | $-75M | $-168M | $153M | $-21M |
| Gross Margin | -6.2% | — | 65.4% | — |
| Operating Margin | -232.3% | — | 12.3% | — |
| Forward P/E | — | — | 24.8x | — |
| Total Debt | $16M | $22M | $70M | $0.00 |
| Cash & Equiv. | $21M | $194M | $1.12B | $4M |
ADGM vs DBVT vs ALKS vs BEAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 24 | May 26 | Return |
|---|---|---|---|
| Adagio Medical Hold… (ADGM) | 100 | 18.9 | -81.1% |
| DBV Technologies S.… (DBVT) | 100 | 349.2 | +249.2% |
| Alkermes plc (ALKS) | 100 | 123.0 | +23.0% |
| HeartBeam, Inc. (BEAT) | 100 | 37.9 | -62.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADGM vs DBVT vs ALKS vs BEAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ADGM is the #2 pick in this set and the best alternative if stability is your priority.
- Beta 0.87 vs DBVT's 1.26
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
- +110.4% vs BEAT's -53.7%
ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
- -11.0% 10Y total return vs BEAT's -81.4%
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
BEAT lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -5.2% revenue growth vs BEAT's -100.0% | |
| Quality / Margins | 9.8% margin vs ADGM's -199.9% | |
| Stability / Safety | Beta 0.87 vs DBVT's 1.26 | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs BEAT's -53.7% | |
| Efficiency (ROA) | 5.4% ROA vs BEAT's -353.1% |
ADGM vs DBVT vs ALKS vs BEAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
ADGM vs DBVT vs ALKS vs BEAT — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 2 of 6 categories
ADGM leads 0 • DBVT leads 0 • BEAT leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and ADGM operate at a comparable scale, with $1.6B and -$143,000 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to ADGM's -199.9%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | -$143,000 | $0 | $1.6B | $0 |
| EBITDAEarnings before interest/tax | -$67M | -$112M | $212M | -$21M |
| Net IncomeAfter-tax profit | -$75M | -$168M | $153M | -$21M |
| Free Cash FlowCash after capex | -$24M | -$151M | $392M | -$15M |
| Gross MarginGross profit ÷ Revenue | -6.2% | — | +65.4% | — |
| Operating MarginEBIT ÷ Revenue | -232.3% | — | +12.3% | — |
| Net MarginNet income ÷ Revenue | -199.9% | — | +9.8% | — |
| FCF MarginFCF ÷ Revenue | -115.6% | — | +25.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — | +28.2% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -106.3% | +91.5% | -4.1% | +22.2% |
Valuation Metrics
Evenly matched — DBVT and ALKS and BEAT each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $15M | $1712.35T | $5.9B | $35M |
| Enterprise ValueMkt cap + debt − cash | $10M | $1712.35T | $4.9B | $31M |
| Trailing P/EPrice ÷ TTM EPS | -0.27x | -0.76x | 24.76x | -1.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 17.25x | — |
| Price / SalesMarket cap ÷ Revenue | 54.49x | — | 4.00x | — |
| Price / BookPrice ÷ Book value/share | 0.73x | 0.66x | 3.28x | 11.27x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.28x | — |
Profitability & Efficiency
ALKS leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-8 for ADGM. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADGM's 0.82x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs BEAT's 1/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -7.5% | -130.2% | +8.8% | -5.7% |
| ROA (TTM)Return on assets | -189.8% | -89.0% | +5.4% | -3.5% |
| ROICReturn on invested capital | — | — | +18.9% | — |
| ROCEReturn on capital employed | -374.1% | -145.7% | +14.2% | -4.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 7 | 1 |
| Debt / EquityFinancial leverage | 0.82x | 0.13x | 0.04x | — |
| Net DebtTotal debt minus cash | -$4M | -$172M | -$1.0B | -$4M |
| Cash & Equiv.Liquid assets | $21M | $194M | $1.1B | $4M |
| Total DebtShort + long-term debt | $16M | $22M | $70M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -36.69x | -189.82x | 32.30x | — |
Total Returns (Dividends Reinvested)
Evenly matched — DBVT and ALKS each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $1,053 for ADGM. Over the past 12 months, DBVT leads with a +110.4% total return vs BEAT's -53.7%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs ADGM's -52.8% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.8% | +4.9% | +25.3% | -64.2% |
| 1-Year ReturnPast 12 months | -26.1% | +110.4% | +16.5% | -53.7% |
| 3-Year ReturnCumulative with dividends | -89.5% | +19.7% | +14.5% | -59.1% |
| 5-Year ReturnCumulative with dividends | -89.5% | -69.1% | +60.9% | -81.4% |
| 10-Year ReturnCumulative with dividends | -89.5% | -87.0% | -11.0% | -81.4% |
| CAGR (3Y)Annualised 3-year return | -52.8% | +6.2% | +4.6% | -25.8% |
Risk & Volatility
Evenly matched — ADGM and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADGM is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs BEAT's 21.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.87x | 1.26x | 1.00x | 1.27x |
| 52-Week HighHighest price in past year | $2.58 | $26.18 | $36.60 | $4.00 |
| 52-Week LowLowest price in past year | $0.74 | $7.53 | $25.17 | $0.54 |
| % of 52W HighCurrent price vs 52-week peak | +36.9% | +76.3% | +96.7% | +21.8% |
| RSI (14)Momentum oscillator 0–100 | 37.3 | 48.1 | 60.2 | 37.3 |
| Avg Volume (50D)Average daily shares traded | 124K | 252K | 2.3M | 1.6M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 29.9% for ALKS (target: $46).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | $46.33 | $46.00 | — |
| # AnalystsCovering analysts | — | 15 | 28 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | 0.0% |
ALKS leads in 2 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 3 categories are tied.
ADGM vs DBVT vs ALKS vs BEAT: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is ADGM or DBVT or ALKS or BEAT a better buy right now?
For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.
2% revenue growth year-over-year, versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ADGM or DBVT or ALKS or BEAT?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -89. 5% for Adagio Medical Holdings, Inc. (ADGM). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus ADGM's -89. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ADGM or DBVT or ALKS or BEAT?
By beta (market sensitivity over 5 years), Adagio Medical Holdings, Inc.
(ADGM) is the lower-risk stock at 0. 87β versus HeartBeam, Inc. 's 1. 27β — meaning BEAT is approximately 47% more volatile than ADGM relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 82% for Adagio Medical Holdings, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ADGM or DBVT or ALKS or BEAT?
By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.
2% versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). On earnings-per-share growth, the picture is similar: Adagio Medical Holdings, Inc. grew EPS 27. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ADGM or DBVT or ALKS or BEAT?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ADGM or DBVT or ALKS or BEAT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ADGM or DBVT or ALKS or BEAT better for a retirement portfolio?
For long-horizon retirement investors, Adagio Medical Holdings, Inc.
(ADGM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Both have compounded well over 10 years (ADGM: -89. 2%, BEAT: -81. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ADGM and DBVT and ALKS and BEAT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.